LLC also announced the launch of mPACT(TM) - Multaq Partnership for Appropriate Care and Treatment - the Risk Evaluation and Mitigation Strategy (REMS) developed by sanofi-aventis U.
cialis sin receta barcelona espana |
"
Multaq is to be given twice daily as a 400 mg tablet and should be taken as one tablet with the morning and evening meals. Most common adverse reactions are diarrhea, nausea, vomiting, abdominal pain, asthenia (weakness) and cutaneous rash. |
1mg/dL following Multaq treatment initiation. Sanofi-aventis is listed in Paris and in New York . |
| LLC. Potassium levels should be maintained in the normal range pre and during administration. |
The patients enrolled in ANDROMEDA had relatively severe heart failure and had been hospitalized, or referred to a specialty heart failure clinic for worsening symptoms.
switch from xanax to klonipin nicotine valium vicodin marijuana ecstacy alcohol |
The risk mitigation program consists of a Communication Plan for HCPs, a medication guide for patients and post-marketing surveillance. In contrast, in ATHENA, all patients had a history of AF/AFL, and 71% of patients had no heart failure, 25% were NYHA class I or II, and only 4% were class III. |
| "Sanofi-aventis’ commitment to research and development in this area is rewarded today, and we hope it will benefit many patients suffering from this disease. |
This unstable population corresponds to the population of the ANDROMEDA trial in which patients receiving dronedarone had a greater than 2-fold increase in mortality compared to placebo. |
"The FDA approval of Multaq is an important milestone in the management of atrial fibrillation or atrial flutter that demonstrates the commitment of sanofi-aventis to provide patients and physicians with important new medicines in therapeutic areas with significant healthcare needs," said Christopher A. |
| 5 million people in the European Union. Most common adverse reactions are diarrhea, nausea, vomiting, abdominal pain, asthenia (weakness) and cutaneous rash. |
5 million people in the European Union. |
The FDA approval is based on five international, multi-center, randomized clinical trials involving nearly 6,300 patients.
Serum creatinine levels increase by about 0. |
| Multaq is the first drug approved in the United States that has shown a clinical benefit to reduce cardiovascular hospitalization in patients with AF/AFL. |
027]. |
"Sanofi-aventis is proud of its ability to bring innovative therapies to market and contribute to reducing the public health burden of atrial fibrillation. |
| The risk mitigation program consists of a Communication Plan for HCPs, a medication guide for patients and post-marketing surveillance. |
About dronedarone (Multaq)
Multaq, discovered and developed by sanofi-aventis, is one of the major therapeutic innovations in patients with atrial fibrillation in the last twenty years. and represents one-third of hospitalizations for arrhythmia in Europe. |
Patients with atrial fibrillation (AF) or atrial flutter (AFL) soon will have a new treatment option to help improve current management of their disease. |
|
A registration dossier of Multaq is also under regulatory review by the European Medicines Agency (EMEA).
About sanofi-aventis
Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. |
The ATHENA and ANDROMEDA trials provided two sets of data supporting the assessment of the product's benefit risk ratio in two significantly different patient populations. "Sanofi-aventis’ commitment to research and development in this area is rewarded today, and we hope it will benefit many patients suffering from this disease. |
S. |
| Most common adverse reactions are diarrhea, nausea, vomiting, abdominal pain, asthenia (weakness) and cutaneous rash. |
"Based on clinical studies, Multaq reduces the risk of cardiovascular hospitalizations in patients with atrial fibrillation / atrial flutter, this outcome could change the way we approach the management of the disease.
The efficacy and safety of Multaq 400 mg twice daily was evaluated in five controlled studies, ATHENA, ANDROMEDA, EURIDIS, ADONIS, and DAFNE, involving nearly 6,300 patients including more than 3200 patients who received Multaq. |
The FDA approval is based on five international, multi-center, randomized clinical trials involving nearly 6,300 patients.
The patient population enrolled in the ANDROMEDA and ATHENA studies was significantly different. |
| and represents one-third of hospitalizations for arrhythmia in Europe. |
The patients enrolled in ANDROMEDA had relatively severe heart failure and had been hospitalized, or referred to a specialty heart failure clinic for worsening symptoms. |
The ANDROMEDA and ATHENA trials were published in the New England Journal of Medicine (NEJM) respectively in 2008 and 2009. |
| LLC also announced the launch of mPACT(TM) - Multaq Partnership for Appropriate Care and Treatment - the Risk Evaluation and Mitigation Strategy (REMS) developed by sanofi-aventis U. |
Food and Drug Administration (FDA) has approved Multaq (dronedarone) 400 mg Tablets. |
For full prescribing information, please visit http://products. |